Pfizer cuts the number of vaccines it planned to make

In recent weeks, Pfizer has anticipated that it will produce just 50 million vaccines against Covid-19. The amount is reduced to half of what it had previously promised due to many raw material supply problems. The drugmaker originally planned to manufacture 100 million antidotes to combat the disease before the end of the year. But now those numbers have dropped considerably.

Because Pfizer's vaccine is based on a 2-dose regimen, it means that the 50 million vaccines they will make will be able to inoculate only 25 million people.

A company spokeswoman reported that expanding the raw material supply chain took longer than expected. Noting in the same way that the results of the clinical trial will also arrive late. Which will result in a lower number of doses being produced by the end of 2020.

Pfizer requests an emergency authorization

In November, Pfizer applied for an emergency authorization to the US regulatory bodies, so that its vaccines against Covid-19 were approved. US authorities expect the vaccine to receive official approval this month. The country's government believes that its first allocation of the doses will include 6.4 million of them, which will be followed by other packages later.

For their part, the UK regulatory authorities anticipated official approval and has already authorized the authorization of vaccine doses in the country. A decision that generated different questions in Europe and the United States for considering it premature.

Among the voices that spoke out in this regard is the expert epidemiologist Anthony Fauci, the highest US authority on infectious diseases. Who indicated that the approach used by the UK was questionable, and referred to it as follows:

"If you go fast and do it superficially, people will not want to get vaccinated"

He also noted that the UK had not made the decision so carefully, insisting that they had been a couple of days early. To which he added that he didn't think that made much of a difference.

But, after making this public statement, Fauci retraced his words;

"Our process takes longer than that of the United Kingdom, that is the reality, I did not want to imply any oversight despite the fact that the statement came out that way."

The epidemiologist added that he had great confidence in the work of that country, both in the scientific and regulatory areas.

However, Fauci was not the only one to ask for caution regarding the situation of the British authorities. The fears refer to the possibility of a repeat of what happened in Russia and China, where some vaccines received approvals before the phase 3 result was presented.

Share this information!